Thymalin: The Thymus Immune Peptide Complex
A polypeptide complex isolated from the thymus that drives T-lymphocyte maturation. Researched since the Soviet era by Khavinson’s group — and structurally distinct from both Thymosin Alpha-1 and Thymulin.
How It Works
In human hematopoietic stem-cell culture, Thymalin reduced the stem markers CD44 and CD117 by 2–3× while raising the mature T-cell marker CD28 by 6.8× — indicating a push toward mature T-lymphocyte differentiation (Khavinson 2020, PMID 33237528).
The KE dipeptide (Lys-Glu, the Vilon sequence) is reported to activate macrophages, blood lymphocytes, thymocytes and neutrophils, boosting cellular immunity and nonspecific resistance (Linkova & Khavinson 2023, PMID 37686182).
The EW dipeptide (Glu-Trp, the Thymogen sequence) is modeled to reduce angiotensin-induced vasoconstriction and preserve endothelium-dependent relaxation via ACE2 interaction — the rationale behind Thymalin’s study in severe respiratory illness (PMID 37686182).
In monocyte/macrophage (THP-1) cell lines, thymus-derived peptides modulated proliferative activity and inflammatory signaling pathways (Int J Mol Sci 2022, PMID 35408963).
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- Thymalin is a polypeptide complex isolated from the thymus — not a single peptide; its two best-characterized active dipeptides are KE (Lys-Glu) and EW (Glu-Trp). (PMID 33237528, 37686182)
- In human stem-cell culture it shifted cells toward mature CD28+ T-lymphocytes, the cells depleted in severe COVID-19. (PMID 33237528)
- It has a long Russian clinical history — trauma support, oncology adjunct, and acute respiratory illness — dating to the 1980s. (PMID 6547012, 3839953)
- It was studied within complex therapy for middle-aged and elderly severe COVID-19 patients. (PMID 33575961, 37686182)
- It is mechanistically distinct from Thymosin Alpha-1 (a single 28-amino-acid peptide) and from Thymulin (a zinc-dependent nonapeptide).
- It is not FDA-approved; clinical evidence is largely from Russian/Soviet literature and modern cell-culture work, not large Western randomized trials.
- The 6.8× CD28 figure is from an in-vitro hematopoietic stem-cell study, not a human clinical endpoint — do not read it as a COVID-19 cure.
- Long-term safety data in healthy adults using it for "longevity" is essentially absent.
- Optimal dose, route, and cycling for non-clinical use are not established by controlled trials.
- Whether oral KE/EW dipeptide supplements reproduce injected Thymalin’s effects is unproven.
Frequently Asked Questions
What is Thymalin?
Thymalin is a polypeptide complex extracted from the thymus gland that regulates immune function. It is not a single molecule — its two best-studied active components are the dipeptides KE (Lys-Glu) and EW (Glu-Trp). It has been used in Russian clinical medicine since the 1980s to support immunity in trauma, oncology, and respiratory illness. (PMID 33237528)
How is Thymalin different from Thymosin Alpha-1 and Thymulin?
Thymosin Alpha-1 is a single defined 28-amino-acid peptide; Thymulin is a zinc-dependent nonapeptide thymic hormone. Thymalin is neither — it is a multi-peptide thymus extract whose activity is attributed mainly to the KE and EW dipeptides. All three are thymic immunomodulators, but they differ in structure, mechanism detail, and regulatory status.
Is there evidence Thymalin helps with COVID-19?
Russian researchers reported using Thymalin within complex therapy for severe COVID-19 in middle-aged and elderly patients, and cell-culture work shows it raises the mature T-cell marker CD28 (which is depleted in severe COVID-19) by about 6.8×. This is early, largely single-group evidence — not a substitute for vaccines or approved antivirals. (PMID 33575961, 33237528)
How is Thymalin dosed?
Russian clinical protocols describe 5–10 mg of lyophilized Thymalin reconstituted in sterile saline and given intramuscularly once daily for 5–10 days, with repeat short courses in geroprotection regimens. These are figures from the clinical literature, not a recommendation — optimal dosing for non-clinical use is not established. (PMID 12577695)
Is Thymalin FDA-approved?
No. Thymalin is registered and used in Russia and some post-Soviet states but is not FDA-approved and is not a recognized drug in the US or EU. Treat it as a research compound, not a medicine.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
Thymalin is not FDA-approved. Citations are to published research; figures from cell-culture or animal studies are labeled as such and do not predict human clinical outcomes.
Consult a licensed physician before using any peptide. Do not use research compounds to self-treat disease.